Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

A High-Throughput Screening Identifies MicroRNA Inhibitors That Influence Neuronal Maintenance and/or Response to Oxidative Stress.

Pallarès-Albanell J, Zomeño-Abellán MT, Escaramís G, Pantano L, Soriano A, Segura MF, Martí E.

Mol Ther Nucleic Acids. 2019 Jun 20;17:374-387. doi: 10.1016/j.omtn.2019.06.007. [Epub ahead of print]

2.

MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

Majem B, Parrilla A, Jiménez C, Suárez-Cabrera L, Barber M, Marín A, Castellví J, Tamayo G, Moreno-Bueno G, Ponce J, Matias-Guiu X, Alameda F, Romero I, Sánchez JL, Pérez-Benavente A, Moran S, Esteller M, Reventós J, Rigau M, Gil-Moreno A, Segura MF, Santamaría A.

Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.

PMID:
31278368
3.

Interplay Between ncRNAs and Cellular Communication: A Proposal for Understanding Cell-Specific Signaling Pathways.

Ramón Y Cajal S, Segura MF, Hümmer S.

Front Genet. 2019 Apr 2;10:281. doi: 10.3389/fgene.2019.00281. eCollection 2019.

4.

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma.

Soriano A, Masanas M, Boloix A, Masiá N, París-Coderch L, Piskareva O, Jiménez C, Henrich KO, Roma J, Westermann F, Stallings RL, Sábado C, de Toledo JS, Santamaria A, Gallego S, Segura MF.

Cell Mol Life Sci. 2019 Jun;76(11):2231-2243. doi: 10.1007/s00018-019-03041-4. Epub 2019 Feb 15.

5.

Targeting of epigenetic regulators in neuroblastoma.

Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R, Roma J, Toledo JS, Gallego S, Segura MF.

Exp Mol Med. 2018 Apr 27;50(4):51. doi: 10.1038/s12276-018-0077-2. Review.

6.

Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.

Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Cartón-García F, Macaya I, de Marcondes PG, Anguita E, Masanas M, Jiménez-Flores LM, Martínez-Barriocanal Á, Nieto R, Segura MF, Schwartz S Jr, Mariadason JM, Arango D.

Br J Cancer. 2018 Jan;118(1):106-116. doi: 10.1038/bjc.2017.420. Epub 2017 Dec 5.

7.

MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells.

Sánchez-Cid L, Pons M, Lozano JJ, Rubio N, Guerra-Rebollo M, Soriano A, Paris-Coderch L, Segura MF, Fueyo R, Arguimbau J, Zodda E, Bermudo R, Alonso I, Caparrós X, Cascante M, Rafii A, Kang Y, Martínez-Balbás M, Weiss SJ, Blanco J, Muñoz M, Fernández PL, Thomson TM.

Oncotarget. 2017 Sep 7;8(48):83384-83406. doi: 10.18632/oncotarget.20698. eCollection 2017 Oct 13.

8.

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands.

Almazán-Moga A, Zarzosa P, Molist C, Velasco P, Pyczek J, Simon-Keller K, Giralt I, Vidal I, Navarro N, Segura MF, Soriano A, Navarro S, Tirado OM, Ferreres JC, Santamaria A, Rota R, Hahn H, Sánchez de Toledo J, Roma J, Gallego S.

Br J Cancer. 2017 Oct 24;117(9):1314-1325. doi: 10.1038/bjc.2017.305. Epub 2017 Sep 7.

9.

Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions.

Segura MF, Jubierre L, Li S, Soriano A, Koetz L, Gaziel-Sovran A, Masanas M, Kleffman K, Dankert JF, Walsh MJ, Hernando E.

Oncotarget. 2017 Apr 18;8(16):26298-26311. doi: 10.18632/oncotarget.15459.

10.

Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma.

Almazán-Moga A, Zarzosa P, Vidal I, Molist C, Giralt I, Navarro N, Soriano A, Segura MF, Alfranca A, Garcia-Castro J, Sánchez de Toledo J, Roma J, Gallego S.

Stem Cells Int. 2017;2017:7507380. doi: 10.1155/2017/7507380. Epub 2017 Jan 24.

11.

Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis.

Torres S, Garcia-Palmero I, Bartolomé RA, Fernandez-Aceñero MJ, Molina E, Calviño E, Segura MF, Casal JI.

J Pathol. 2017 May;242(1):39-51. doi: 10.1002/path.4874. Epub 2017 Mar 7.

PMID:
28054337
12.

MicroRNA-182 targets SMAD7 to potentiate TGFβ-induced epithelial-mesenchymal transition and metastasis of cancer cells.

Yu J, Lei R, Zhuang X, Li X, Li G, Lev S, Segura MF, Zhang X, Hu G.

Nat Commun. 2016 Dec 20;7:13884. doi: 10.1038/ncomms13884.

13.

Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.

Zarzosa P, Navarro N, Giralt I, Molist C, Almazán-Moga A, Vidal I, Soriano A, Segura MF, Hladun R, Villanueva A, Gallego S, Roma J.

Clin Transl Oncol. 2017 Jan;19(1):44-50. doi: 10.1007/s12094-016-1557-2. Epub 2016 Oct 7. Review.

PMID:
27718156
14.

Fas apoptosis inhibitory molecules: more than death-receptor antagonists in the nervous system.

Planells-Ferrer L, Urresti J, Coccia E, Galenkamp KM, Calleja-Yagüe I, López-Soriano J, Carriba P, Barneda-Zahonero B, Segura MF, Comella JX.

J Neurochem. 2016 Oct;139(1):11-21. doi: 10.1111/jnc.13729. Epub 2016 Aug 3. Review.

15.

BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.

Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF.

Oncogene. 2016 Sep 29;35(39):5179-90. doi: 10.1038/onc.2016.50. Epub 2016 Mar 21.

PMID:
26996667
16.

MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.

Soriano A, París-Coderch L, Jubierre L, Martínez A, Zhou X, Piskareva O, Bray I, Vidal I, Almazán-Moga A, Molist C, Roma J, Bayascas JR, Casanovas O, Stallings RL, Sánchez de Toledo J, Gallego S, Segura MF.

Oncotarget. 2016 Feb 23;7(8):9271-87. doi: 10.18632/oncotarget.7005.

17.

SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150.

Barbáchano A, Fernández-Barral A, Pereira F, Segura MF, Ordóñez-Morán P, Carrillo-de Santa Pau E, González-Sancho JM, Hanniford D, Martínez N, Costales-Carrera A, Real FX, Pálmer HG, Rojas JM, Hernando E, Muñoz A.

Oncogene. 2016 Jun 9;35(23):2991-3003. doi: 10.1038/onc.2015.366. Epub 2015 Oct 12.

18.

[Novel micro RNA-based therapies for the treatment of neuroblastoma].

Boloix A, París-Coderch L, Soriano A, Roma J, Gallego S, Sánchez de Toledo J, Segura MF.

An Pediatr (Barc). 2016 Aug;85(2):109.e1-109.e6. doi: 10.1016/j.anpedi.2015.07.016. Epub 2015 Aug 29. Review. Spanish.

19.

Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.

Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E.

Mol Cell. 2015 Jul 2;59(1):75-88. doi: 10.1016/j.molcel.2015.05.009. Epub 2015 Jun 4.

20.

TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.

Galenkamp KM, Carriba P, Urresti J, Planells-Ferrer L, Coccia E, Lopez-Soriano J, Barneda-Zahonero B, Moubarak RS, Segura MF, Comella JX.

Mol Cancer. 2015 Mar 19;14:62. doi: 10.1186/s12943-015-0329-x.

Supplemental Content

Loading ...
Support Center